Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of Cerebral Histiocytosis With Low Dose of Cobimetinib: A Report of 2 Cases.

Neurology(R) neuroimmunology & neuroinflammation - 1 May 2024

Schubert Charlotte, Schiffmann Insa, Farschtschi Said C, Emile Jean-François, Friese Manuel A

Abstract excerpt

OBJECTIVES: Histiocytic disorders are pathologic expansions of myeloid cells in multiple organs, including the CNS. They share activation of the MAP kinase pathway due to either BRAFV600E variant or other variants in the RAS-RAF-MEK-ERK pathway. The rarity and heterogeneity of the disease only enable therapy through pathophysiologic considerations. METHODS: We present 2 histiocytosis cases without BRAF sequence...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azetidines
Share to Mitogen-Activated Protein Kinase Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Piperidines

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 38588479
DOI: 10.1212/NXI.0000000000200233
PMCID: PMC11010243

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of Cerebral Histiocytosis With Low Dose of Cobimetinib: A Report of 2 Cases.PMID 38588479Read ↗

Histiocytosis.Semantic proximity Read ↗

[Erdheim-Chester disease: a rare histiocytosis with outstanding response to cobimetinib.]Semantic proximity Read ↗

RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition.Semantic proximity Read ↗

Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variantsSemantic proximity Read ↗

Multisystem ALK-positive histiocytosis: a multi-case study and literature reviewSemantic proximity Read ↗

Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenibSemantic proximity Read ↗

Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report.Semantic proximity Read ↗

Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim-Chester disease.Semantic proximity Read ↗

Erdheim-Chester Disease Successfully Treated with Front-Line Single-Agent Dabrafenib.Semantic proximity Read ↗

Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma.Semantic proximity Read ↗

Trametinib for a child with refractory Rosai-Dorfman-Destombes disease harboring a novel somatic mutation in MAP2K1.Semantic proximity Read ↗

Erdheim-Chester Disease Due to a Novel Internal Duplication of NRAS: Response to Targeted Therapy with Cobimetinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.